KINTOR PHARMA-B (09939) Reports Interim Results with Net Loss of RMB 83.27 Million, Up 16.47% Year-on-Year
Stock News
Aug 28
KINTOR PHARMA-B (09939) announced its interim results for 2025, showing revenue increased from zero in the same period last year to RMB 6 million. The company recorded a net loss of RMB 83.268 million, representing a 16.47% increase year-on-year, with loss per share of RMB 0.19.
According to the announcement, the revenue increase was primarily attributed to global sales of the company's new high-end cosmetics brand KOSHINÉ. The group will continue to explore different approaches to further advance the global commercialization of its cosmetics products.
The increased loss was mainly due to higher research and development costs and marketing expenses incurred by the group.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.